Clinical trials
DMD clinical trials
Below are recruiting dmd clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07429240RecruitingPhase 1/Phase 2
Gene editing trial for Duchenne muscular dystrophy (ages 2-7)
This trial tests a new gene editing treatment called PBGENE-DMD for boys with Duchenne muscular dystrophy (DMD) whose genetic mutation falls within a specific range of the dystrophin gene (exons 45-55). The goal is to see if it is safe and can help improve muscle function.
Little Rock, ArkansasAges 2–7 - NCT07608432RecruitingPhase 3
Testing a New DMD Treatment Given Every 4 Weeks
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
Hillsborough, North CarolinaAges 4–18 - NCT07587242RecruitingPhase 3
Testing a New Therapy for DMD with Exon 44 Mutations
This study tests whether a new medicine called AOC 1044 (delpacibart zotadirsen) can help boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The medicine works by helping the body skip a damaged part of the gene to make a functional protein.
LeuvenAges 7–16 - NCT07015632Recruiting
Fall risk screening with sensors in Duchenne MD
This study uses a machine-learning tool (like a smart computer program) to help predict fall risk in people with Duchenne Muscular Dystrophy. It involves wearing sensors to track your movement and balance, which could help doctors create safer care plans.
Seoul, JongnoAges 10–30 - NCT05996003RecruitingPhase 2
Exon 44 skipping drug for Duchenne muscular dystrophy
This trial tests a new drug (NS-089/NCNP-02) that aims to help boys with Duchenne muscular dystrophy produce a shorter but still working version of the dystrophin protein. It's for boys who are still walking and have a specific genetic type that can be fixed by skipping a part of the gene called exon 44.
Aurora, ColoradoAges 4–14 - NCT06290713RecruitingPhase 2
Blood flow and exercise study for Duchenne muscular dystrophy
This trial tests if a medicine that improves blood flow, combined with exercise, can help muscles in boys with Duchenne muscular dystrophy. It is for boys who can still walk and are on a stable steroid medication.
Gainesville, FloridaAges 6 years+ - NCT06925269Recruiting
DMD Voice: Interviews with patients and caregivers
This study invites people with Duchenne muscular dystrophy (DMD) and their caregivers to share their experiences through interviews. It focuses on those who have been taking the medication Givinostat for at least two years, or caregivers of patients with limited arm movement.
Yardley, PennsylvaniaAges 10 years+ - NCT07188012RecruitingEarly Phase 1
Gene therapy trial for Duchenne muscular dystrophy in young boys
This trial tests a new gene therapy called SPOT-03 to see if it can help the body make dystrophin, a protein that is missing in Duchenne muscular dystrophy (DMD). It is for boys ages 2 to under 8 who can still walk at least 10 meters.
Shanghai, Shanghai MunicipalityAges 2–7 - NCT07332013Recruiting
Urine titin test for Duchenne muscular dystrophy
This study measures a protein called titin in urine to see if it can help track muscle damage in boys with Duchenne or Becker muscular dystrophy. It also includes healthy boys for comparison.
Philadelphia, PennsylvaniaAges 2–10 - NCT07674758Recruiting
Understanding heart risk in Duchenne and Becker muscular dystrophy
This study looks at heart health in people with Duchenne or Becker muscular dystrophy to find better ways to predict and track heart problems. The goal is to improve future treatment trials.
Sacramento, CaliforniaAges Any age - NCT07423026Recruiting
Remote study using technology to track DMD in young boys
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
OxfordAges 1–3 - NCT07515235Recruiting
DMD Gene Variants and Heart Function in Young Males
This study examines how different genetic changes in the DMD gene affect heart function in boys with dystrophinopathy (a muscle-weakening condition). Understanding this connection may help doctors better monitor and treat heart problems in affected boys.
ThessalonikiAges 2–24 - NCT07092540Recruiting
Baby Duchenne Study: Early Years in Boys With DMD
This study tracks development and health in young boys with Duchenne muscular dystrophy during the first three years of life. It aims to better understand early signs and how the condition progresses, which may help improve care and future treatments.
Rochester, New YorkAges birth–3 years - NCT07766980Recruiting
Nutritional supplement for quality of life in Duchenne muscular dystrophy
This study tests whether a daily nutritional supplement called VM100 can improve quality of life for people with Duchenne muscular dystrophy. If you are 8 or older and your medications have been stable for at least 3 months, you may be able to participate.
Gainesville, FloridaAges 6 years+ - NCT05412394RecruitingPhase 4
Once-weekly steroid for very young children with DMD
This trial tests whether a steroid taken once each week is safe and useful for children with Duchenne muscular dystrophy (DMD). It aims to help slow disease effects in very young children whose diagnosis and lab tests confirm DMD.
Chicago, IllinoisAges 1 month–2.5 years - NCT06224660RecruitingPhase 1
Gene therapy for heart problems in Duchenne muscular dystrophy
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Kansas City, KansasAges 18 years+ - NCT05102916Recruiting
Registry for neuromuscular disorder patients in Switzerland
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
Aarau, Canton of AargauAges birth+ - NCT06581887Recruiting
Measuring behavior and emotions in Duchenne and Becker muscular dystrophy
This study looks at how to measure behavioral and emotional challenges in boys with Duchenne or Becker muscular dystrophy, and in boys without the condition. It aims to find better ways to assess these issues, which could help improve care and treatments.
LondonAges 7–17 - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT04626674RecruitingPhase 1
Gene therapy safety study for non-ambulatory Duchenne
This Phase 1 trial studies a one-time gene therapy treatment (SRP-9001) to see if it is safe and whether it can produce the needed gene activity in people with Duchenne muscular dystrophy (DMD) who are not walking. It may help researchers understand whether this approach could be useful for DMD patients, especially in later stages.
Little Rock, ArkansasAges 2 years+ - NCT05066633RecruitingPhase 3
Metoprolol added to standard care to prevent heart muscle damage
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
Gdansk, Pomeranian VoivodeshipAges 8–17 - NCT06093100Recruiting
Wearable device study for Duchenne muscular dystrophy
This study uses a wearable device to track blood sugar levels and heart rate in people with Duchenne muscular dystrophy. It aims to understand how these factors relate to heart health over time.
Nashville, TennesseeAges 10 years+
Hear when a new DMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dmd?
- Yes. Clin2 currently lists 47 recruiting dmd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dmd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dmd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.